Integrase inhibitor–based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection - Takeaways - MDSpire

Integrase inhibitor–based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection

  • By

  • Banu Karaca

  • Alper Şener

  • Figen Kaptan

  • Deniz Ece

  • Bahar Örmen

  • Ayse Caner

  • May 12, 2026

  • 0 min

Share

  • 1

    Integrase inhibitor-based antiretroviral therapy promotes partial normalization of gut microbiota in HIV-infected patients.

  • 2

    Long-term INSTI therapy enhances beneficial gut bacteria linked to immune recovery and mucosal integrity.

  • 3

    A shift in gut microbiota composition was observed, with increased Firmicutes and decreased Bacteroidetes in treated patients.

  • 4

    Higher CD4+ T cell counts correlated positively with beneficial short-chain fatty acid-producing bacteria.

  • 5

    The findings suggest potential for microbiota-targeted interventions to support immune health in HIV patients.

Original Source(s)

Integrase inhibitor–based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection

  • by Banu Karaca, Alper Şener, Figen Kaptan, Deniz Ece, Bahar Örmen, Ayse Caner

  • May 12, 2026

Related Content

Medical Oddities: Chew on This Cancer Prevention Idea

From gum to gut to memory—medicine gets weirdly clever fast 

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

Limits of Negative Infection Studies in AD

Perspective argues that study design and measurement challenges may obscure potential links between infection and disease